Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Frequently asked questions
What sector does Atara Biotherapeutics, Inc (ATRA) operate in?
Atara Biotherapeutics, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Atara Biotherapeutics, Inc (ATRA) current stock price?
As of the latest data, Atara Biotherapeutics, Inc stock price is $8.45, with a previous close of $8.25. Atara Biotherapeutics, Inc gained $0.20 in the last trading session, representing a 2.42% increase.
What is Atara Biotherapeutics, Inc (ATRA) current market capitalization?
Atara Biotherapeutics, Inc market cap is approximately 76.14 million.
What is Atara Biotherapeutics, Inc (ATRA) Earnings Per Share (EPS)?
The trailing EPS is -$1.22, and the forward EPS is $1.27.
What is Atara Biotherapeutics, Inc (ATRA) EBITDA?
Atara Biotherapeutics, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.29 million.
Does Atara Biotherapeutics, Inc (ATRA) pay dividends?
No. Atara Biotherapeutics, Inc does not pay a dividend.
How did Atara Biotherapeutics, Inc (ATRA) perform in its most recent earnings report?
In the last report (March 31, 2026), Atara Biotherapeutics, Inc posted an EPS surprise of -35.86% and a revenue surprise of -76.28%.
When is Atara Biotherapeutics, Inc (ATRA) next earnings report?
Atara Biotherapeutics, Inc is expected to release its next earnings report on June 30, 2026.
What is Atara Biotherapeutics, Inc (ATRA) beta (volatility) score?
Atara Biotherapeutics, Inc has a beta of 0.090, indicating lower volatility than the overall market.
